CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
276.26MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.3920xvs all stocks
52-Week Change
-36.74%vs all stocks
Market Capitalization
276.26MUSDvs all stocks (USD)
Enterprise Value
129.99MUSDvs all stocks (USD)
Forward P/E
-3.40xvs Biotechnology peers
Price to Book (MRQ)
1.45xvs Biotechnology peers
Enterprise to EBITDA
-2.06xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-32.77%vs Biotechnology peers
Return on Equity (TTM)
-52.15%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-63.12MUSDvs all stocks (USD)
Net Income (TTM)
-57.28MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-56.75MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-39.35MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-59.38MUSDvs all stocks (USD)
Pre-tax Income
-56.02MUSDFY2025 · Dec 31, 2025Net Income
-56.02MUSDFY2025 · Dec 31, 2025EBIT
-59.38MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-59.02MUSDFY2025 · Dec 31, 2025Research & Development
42.05MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
17.30MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.04MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-56.02MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-48.93MUSDFY2025 · Dec 31, 2025Free Cash Flow
-49.07MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
128.65MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-56.02MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
353.78KUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.31MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-400.80KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
833.66KUSDFY2025 · Dec 31, 2025Capital Expenditures
-142.23KUSDFY2025 · Dec 31, 2025Purchase of Investments
-88.60MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-88.74MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.73MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
225.79MUSDFY2025 · Dec 31, 2025Shares Outstanding
64.70MSharesUpdated Sep 27, 2026Float Shares
49.21MSharesUpdated Sep 27, 2026Shares Short
15.55MSharesUpdated Sep 27, 2026Short Ratio
23.83daysvs all stocks
Short % of Shares Outstanding
31.68%vs all stocks
% Held by Insiders
13.82%vs all stocks
% Held by Institutions
55.44%vs all stocks
Total Cash (MRQ)
149.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.32USDUpdated Sep 27, 2026Total Debt (MRQ)
3.63MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0191xvs Biotechnology peers
Current Ratio (MRQ)
19.47xvs Biotechnology peers
Book Value per Share (MRQ)
2.95USDUpdated Sep 27, 2026Total Assets
231.99MUSDvs all stocks (USD)
Total Current Assets
176.25MUSDFY2025 · Dec 31, 2025Total Liabilities
13.50MUSDFY2025 · Dec 31, 2025Total Non-current Assets
55.74MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
3.43MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.07MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
128.65MUSDFY2025 · Dec 31, 2025Other Short-term Investments
44.19MUSDFY2025 · Dec 31, 2025Accounts Payable
1.54MUSDFY2025 · Dec 31, 2025Short-term Debt
397.10KUSDFY2025 · Dec 31, 2025Other Current Liabilities
291.51KUSDFY2025 · Dec 31, 2025Long-term Debt
3.43MUSDFY2025 · Dec 31, 2025Common Stock (Book)
64.65KUSDFY2025 · Dec 31, 2025Retained Earnings
-280.32MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
218.48MUSDvs all stocks (USD)
52-Week Low
3.86USDUpdated Sep 27, 202652-Week High
8.48USDUpdated Sep 27, 202652-Week Change
-36.74%vs all stocks
Beta
0.3920xvs all stocks
50-Day MA
4.67USDUpdated Sep 27, 2026200-Day MA
5.09USDUpdated Sep 27, 2026Avg 10-Day Volume
669.46KSharesUpdated Sep 27, 2026Avg 30-Day Volume
651.69KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.9300USDUpdated Sep 27, 2026Other Income / Expense
311.67KUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.75
Altman Z-Score 10.6: safe zoneNotable
Altman Z-Score: 10.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Invivyd Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Tiansheng Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Wuhan Fingu Electronic Technology Co., Ltd.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Guangzhou S.P.I Design Co., Ltd.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Tectonic Therapeutic Inc.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity